A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
Duke University
GlaxoSmithKline
Novartis
National Institutes of Health Clinical Center (CC)
Jonsson Comprehensive Cancer Center
Compugen Ltd
Tempus AI
N.N. Petrov National Medical Research Center of Oncology
Memorial Sloan Kettering Cancer Center
NextCure, Inc.
Catharina Ziekenhuis Eindhoven
Revolution Medicines, Inc.
Dublin City University